86 results about "Immunoresponse" patented technology

The invention belongs to the field of biological immunity, and discloses a linear B cell epitope of African swine fever virus NP419L protein and application. The epitope sequence shows good immunoreactivity through ASFV positive pig serum recognition verification. The African swine fever positive serum can be identified by using the B cell epitope identified by the invention to carry out ELISA (Enzyme-Linked Immunosorbent Assay) experiment, and the sensitivity of the African swine fever positive serum is superior to that of NP419L protein full length and other truncated fragments. The epitope identified by the invention has high conservative property in reference ASFV strains in a plurality of popular regions in China, and has wide universality and adaptability. The kit can be widely applied to etiological diagnosis, serological diagnosis, immunological detection and disease prevention and treatment of African swine fever viruses, and can be applied to preparation of African swine fever vaccines, pathogenesis research and the like.

The presently disclosed subject matter provides for methods and compositions for treating cancer (e.g., breast cancer). It relates to mutant PIK3CA-targeted TCRs that specifically target a mutant PIK3CA peptide (e.g., a human mutant PIK3CA peptide), and immunoresponsive cells comprising such TCRs. The presently disclosed mutant PIK3CA peptide-specific TCRs have enhanced immune-activating properties, including anti-tumor activity.

To provide immunoresponsive cells having IL-1 superfamily activities with spatiotemporal restriction.SOLUTION: The present invention provides an immunoresponsive cell expressing a modified pro-cytokine of the IL-1 superfamily, where the modified pro-cytokine comprises, from N-terminus to C-terminus, (a) a pro-peptide; (b) a cleavage site recognized by a protease other than caspase-1, cathepsin G, elastase or proteinase 3; and (c) a fragment of a cytokine of the IL-1 superfamily.SELECTED DRAWING: None

The invention relates to the technical field of cell-loaded biological medicine, in particular to a novel efficient nucleic acid delivery method of a carrier siRNA (small interfering Ribonucleic Acid) medicine, which comprises the following steps: constructing a multifunctional nano-carrier taking a biodegradable polymer as a core, the surface of a multifunctional nano-carrier is modified with a targeting ligand, through specific binding of the targeting ligand and a vascular endothelial cell surface receptor and reversible adjustment of penetration promoting molecules on tight connection, the siRNA / carrier compound can efficiently penetrate vascular endothelium including a blood brain barrier, and meanwhile, the siRNA / carrier compound has the advantages that the targeting ligand can be used for preparing a targeted medicine for treating vascular endothelial cells, and the targeted medicine can be used for treating vascular endothelial cells. According to the present invention, the nucleic acid delivery efficiency is significantly improved, the siRNA can be massively delivered into the tumor or the specific tissue cell due to the precise targeting and the efficient penetrating power, and the selected biodegradable polymer and the selected modification molecule have good biocompatibility so as not to cause the obvious immunoreaction and toxicity in the body.

The presently disclosed subject matter provides for methods and compositions for treating cancer (e.g., breast cancer). It relates to mutant PIK3CA-targeted TCRs that specifically target a mutant PIK3CA peptide (e.g., a human mutant PIK3CA peptide), and immunoresponsive cells comprising such TCRs. The presently disclosed mutant PIK3CA peptide-specific TCRs have enhanced immune-activating properties, including anti-tumor activity.

The invention discloses a polyclonal antibody targeting a human CPNE7 variable splicing isomer and application of the polyclonal antibody, and belongs to the technical field of biological medicine. The antigen epitope 'KYKQKRRSYKN' (SEQ ID NO.1) capable of being targeted by the polyclonal antibody provided by the invention is positioned in a common conserved region of all main isomers of CPNE7, and a variable splicing region is not involved. The titer of the obtained antibody serum is as high as 1: 32,000, which indicates that the antibody has extremely high immunoreactivity and sensitivity and can be used for detecting trace proteins. The antibody disclosed by the invention can be used for effectively identifying GST-CPNE7 fusion protein expressed by a prokaryotic system and CPNE7-FL and CPNE7-S protein overexpressed in an eukaryotic system (A549 cells), and the applicability of the antibody in various experimental systems is proved. Therefore, the blank in the prior art can be filled, and a core tool is provided for research of the CPNE7 in the fields of tumor biology, diagnosis and treatment.

To provide a protein adsorption inhibitor that can suppress the adsorption of proteins to surfaces such as immunoreaction vessels and measuring instruments to a high degree, while also reducing variability between measurements. [Solution] Formula (1): Z-{O-[(PO) a (EO) b ]-(AO) c -H]} x A protein adsorption inhibitor comprising an alkylene oxide derivative represented by (the definition of the symbols in the formula is as described in the specification), wherein the cloud point of a 1% by mass aqueous solution of the alkylene oxide derivative is 0°C or higher and 30°C or lower.

This application relates to the field of tumor metabolic biomarker detection technology, and discloses a method for detecting glucose metabolism biomarkers in esophageal cancer based on VAV2-related molecular characteristics. The method includes: performing immunohistochemical staining on esophageal cancer tissue samples to obtain VAV2, EIF3F, MTA1, and HIF-1α protein expression sections; scoring the immunoreaction of each section; calculating a comprehensive glucose metabolism phenotype score based on the molecular hierarchy of the VAV2-EIF3F-MTA1 / HIF-1α glucose metabolism regulatory pathway; and classifying the samples into high-glycolytic, moderate-glycolytic, and low-glycolytic types according to the comprehensive score. This application improves the accuracy and stability of glucose metabolism phenotype discrimination in esophageal cancer.

The present application relates to a kind of based on chemotactic factor CXCL12 mutant modification double specific fusion protein and its application as immune checkpoint molecule targeted degradation platform in tumor immunotherapy, belong to biological medicine field.The specific problem of the present application is how to effectively enhance the effect of tumor immunotherapy, especially solve the problem of immune escape phenomenon in tumor microenvironment in traditional immunotherapy.To this end, the present application proposes a new KineTAC targeted degradation platform, specifically designs a new chemotactic factor CXCL12 and target protein binding polypeptide (such as anti-PD-1 / PD-L1 monoclonal antibody, anti-LAG-3 monoclonal antibody, etc.) Fusion expression protein molecule, enhance its binding affinity with receptor CXCR4 and CXCR7, and avoid stimulating tumor cell growth proliferation.The fusion protein can target and degrade the immunosuppressive molecules on the surface of tumor cells and immune cells, thereby enhancing the immune response of immune cells and improving the anti-tumor effect.

The invention relates to the technical field of tumor immunotherapy, in particular to an HLA restrictive neoantigen polypeptide based on malignant ascites tumor cells and application of the HLA restrictive neoantigen polypeptide. The invention provides cholangiocarcinoma neoantigen polypeptide. The amino acid sequence of the neoantigen polypeptide is shown as SEQ ID NO.1, 2 or 3. The tumor neoantigen polypeptide is separated and screened from malignant ascites of a biliary duct cancer patient, has high affinity with HLA molecules, can stimulate generation of tumor specific T cells, further generates immune response of targeted tumor cells, can be used as a target spot for clinical treatment or diagnosis of tumors, and has good application prospects. Good application prospects are realized in tumor immunotherapy.

The invention discloses a preparation method and application of an intelligent nano regulator for tumor photoimmunotherapy, and belongs to the technical field of fine chemical engineering. The intelligent nano regulator is formed by assembling an amphiphilic polymer modified by an immunologic adjuvant Resiquimod (R848) and biotin and a small molecule photosensitizer Try5-Ph-3F together. The nano regulator can be effectively taken by cancer cells and positioned in endoplasmic reticulum, and has good tumor targeting ability. Under illumination, the photosensitizer generates a large amount of reactive oxygen species (ROS) to cause endoplasmic reticulum aggression so as to promote release of immune injury related molecular patterns (DAMPs) and promote maturation of dendritic cells (DCs), in addition, R848 is released in a tumor slightly acidic environment, and maturation of DCs is promoted. And the two drugs cooperate to promote the outbreak of immune response, so that the host obtains stronger and longer-time anti-tumor ability.

The invention provides an enterobacter carrying a CD176 antigen and application thereof, the 16S rRNA gene sequence of the enterobacter has 99% consistency with the 16S rRNA gene sequence of Escherichia coli, the enterobacter can express the CD176 antigen and generate a CD176 antibody through immune induction, and the enterobacter is preserved in the China General Microbiological Culture Collection Center (CGMCC) with the preservation number of CGMCC No.27745. The bacterium can be used as an antigen for inducing CD176-targeted immunoreaction, can be used as an engineering bacterium, and has wide application.

The invention discloses a preparation method and application of a PSA-ACT compound recombinant protein. The preparation method comprises the following steps: obtaining gene segments of recombinant PSA and ACT proteins; respectively connecting the gene segments to starting vectors to form corresponding connectors; carrying out conversion and screening operation on the linker to obtain a corresponding recombinant plasmid; carrying out transformation, transfection, induction and fermentation broth separation and purification operation on the recombinant plasmid to obtain recombinant PSA and ACT proteins; then activating PSA recombinant protein by using metalloproteinase, and then mixing ACT with the activated PSA to obtain a mixture containing the PSA, ACT and a PSA-ACT compound; and finally, purifying by using an ion exchange chromatography technology and a hydrophobic chromatography technology in sequence to obtain the high-purity and high-activity PSA-ACT compound. According to the method, the spontaneous reaction of ACT and activated PSA is utilized, other chemical cross-linking agents are not needed, the cost can be reduced, and the recombinant protein can be produced on a large scale; the PSA-ACT recombinant protein prepared by the method disclosed by the invention has very strong immunoreactivity.

This invention relates to an immunoassay kit and its detection system. The kit includes reagent 1 and reagent 2. The method of using the kit includes the following steps: adding a test sample containing the target molecule to containers 1 and 2 respectively; then adding an α dose of reagent 1 and reagent 2 to container 1 and a β dose of reagent 1 and reagent 2 to container 2 to perform two parallel immunoassays on the test sample; wherein the ratio of the sum of the contents of the first antibody (or antigen) and the second antibody (or antigen) in the reagents added to container 1 to the content of the target molecule is different from the ratio of the sum of the contents of the first antibody (or antigen) and the second antibody (or antigen) in the reagents added to container 2 to the content of the target molecule. The method of using the kit of this invention can directly measure up to 10 6 High sample concentrations at the ng / ml level.

The present invention provides an in vitro method for producing an immunoreactive substance against human cancer cells infected with an HPV16-related virus, the method comprising the step of expressing at least a partial nucleic acid sequence encoding an immunoreactive substance obtained from immune cells stimulated with a complex (stimulatory complex) comprising a human leukocyte antigen (HLA) and a stimulatory peptide, wherein the stimulatory peptide (i) comprises an amino acid sequence selected from SEQ ID NO: 1 and SEQ ID NO: 2, wherein the HLA is derived from the HLA supertype HLA-A01, (ii) comprises the amino acid sequence of SEQ ID NO: 11, wherein the HLA is derived from the HLA supertype HLA-A02, or (iii) comprises an amino acid sequence selected from SEQ ID NOs: 34 to 37, wherein the HLA is derived from the HLA supertype HLA-A03. (iv) the HLA is derived from HLA supertype HLA-A24; (v) the HLA is derived from HLA supertype HLA-B07; or (vi) the HLA is derived from HLA supertype HLA-B15; and an HPV16-derived peptide consisting of the same amino acid sequence as the stimulatory peptide has been verified to be presented by human HPV16-positive cancer cells, as well as methods and uses related thereto.

The invention belongs to the field of polymer chemistry and biomedical engineering, and discloses a construction method and application of a biomimetic membrane coated drug-loaded nano system. According to the system disclosed by the invention, small-molecule traditional Chinese medicine (sinomenine) is loaded in mesopores, and homologous cell membranes wrap drug-loaded nanoparticles to obtain a final nano-drug system which can effectively and passively target nasopharyngeal carcinoma cells. The sinomenine can cooperate with photothermal therapy to jointly induce mitochondrial injury, promote cell apoptosis and cause ICD immunoreaction, the sinomenine inhibits PD-L1 expression to relieve immunosuppression of T cells, meanwhile, infiltration of cytotoxic T cells in tumor sites is increased, distant metastasis of nasopharyngeal carcinoma can be inhibited by inhibiting MMPs and PD-L1, and the nasopharyngeal carcinoma can be inhibited by inhibiting MMPs and PD-L1. Therefore, the effects of enhancing nasopharynx cancer immunotherapy and inhibiting metastasis are achieved.

The application discloses a PSAP-3 protein fragment and application thereof in human echinococcosis. The polypeptide comprises an amino acid sequence as shown in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4. The application further discloses a recombinant protein or a mutation thereof, wherein the recombinant protein comprises an amino acid sequence as shown in SEQ ID NO:5, and the amino acid sequence of the mutation has at least 80% identity with the amino acid sequence of the recombinant protein. The immunoreaction rate of the PSAP-3 recombinant protein of the application is 100%, the echinococcosis can be effectively detected, the positive detection rate is 96%, the negative detection rate is 90%, and the positive patient that cannot be detected by Egr can be detected.

The application belongs to the technical field of disease detection, and particularly relates to application of triphenylmethane compounds in detection of Alzheimer's disease. The application is accidentally discovered that triphenylmethane compounds, especially crystal violet, can be inserted into misfolded beta-sheets of A beta oligomers, so as to cause change of spectrum. Macroscopically, oxidation and discoloration are caused, so that the triphenylmethane compounds can be used for monitoring and early screening of Alzheimer's disease patients. Compared with antigen-antibody preparation of antigen-antibody immunoreaction products, the product in the application has the defects of complicated antigen-antibody preparation and high cost, and the product in the application has low cost. Meanwhile, the main component of the application is a chemical reagent, has good stability, does not need refrigeration storage condition, is convenient to transport, and is convenient to use. Meanwhile, the technical scheme of the application effectively avoids the cleaning process of enzyme-labeled plates and chemiluminescence experiments, and does not need special equipment, so that the basic medical institutions can use the application, and therefore the application has good practical application value and application prospect.

The application discloses a high-recognition and low-scattering quantum dot tubular assembly structure immunochromatography probe and a preparation method and application thereof, and first prepares a nickel-hydrazine complex nanorod, performs etching to obtain a one-dimensional hollow tubular silicon dioxide nanotube, performs mercapto-modification, constructs an oil-soluble tubular assembly through multi-layer assembly of quantum dots, transfers the assembly to an aqueous solvent through an efficient alkylsilane phase transfer strategy, deposits a thin and dense silicon oxide layer on the surface of the assembly to protect the assembly, and simultaneously performs carboxylation and coupling of a novel coronavirus antigen N protein antibody based on the silicon oxide layer to obtain a fluorescent probe. The one-dimensional hollow tubular material is used as a carrier of a signal tag, and due to double optimization of signal amplification effect and immunoreaction efficiency, the sensitivity of a lateral flow immunochromatography platform is improved, and important scientific basis is provided for early discovery, early treatment and early prevention and control of virus infection.

The invention discloses a small peptide and application thereof in preparation of a medicine for treating retinal artery occlusion, and the amino acid sequence of the small peptide is shown as SEQ ID NO.1. The small peptide TAT-PQ has the advantages that by enhancing SUMOylation modification in retinal ganglion cells, inhibiting liquid-liquid phase separation of FXR1 and reducing the translation level of apoptosis-related protein, the apoptosis-related protein can be inhibited, and the apoptosis-related protein can be inhibited. Therefore, the apoptosis of the mouse retinal artery cells is effectively reduced. In addition, the TAT can directly introduce the fused small peptide into the cell, so that the problem of the approach of the drug entering the cell is solved, and the convenience and effectiveness of drug administration are greatly improved. The small peptide does not have immunogenicity, so that the risk of immunoreaction is reduced, and the continuous effectiveness of secondary and above administration is ensured; therefore, the small peptide provided by the invention has a great application prospect in preparation of medicines for treating retinal artery occlusion.

The invention discloses an electrochemical luminescence immunosensor for detecting ochratoxin A (OTA), and belongs to the technical field of biological detection. The sensor comprises an electrochemical luminescence probe and an electrochemical luminescence electrode, wherein the probe is prepared by coupling Tb-MOF subjected to carboxyl activation with an OTA antibody; the electrode is prepared by modifying Au-Ag NPs and then incubating with an OTA coating antigen. According to the invention, qualitative or quantitative analysis of OTA is realized by detecting the intensity of an electrochemical luminescence signal based on a competitive immunoreaction principle. The sensor has the advantages of being high in sensitivity, easy and convenient to operate, low in background signal, wide in linear range (0.0001-1000 ng / mL) and the like, is suitable for rapid detection of OTA in actual samples such as grains and feed, has the recovery rate of 92%-104%, and has good application prospects.

The application discloses a Clostridium perfringens Mbp gene and application thereof, and the nucleotide sequence of the gene is shown as SEQ ID NO. 3. The application extracts the whole genome from a virulent strain of Clostridium perfringens, designs primers to amplify the Mbp gene, and uses a prokaryotic expression method to prepare a recombinant Mbp protein. The immunoprotective effect is evaluated by using an animal experiment, and it is found for the first time that the Clostridium perfringens protein Mbp has good immunoreactivity and can significantly reduce the clinical symptoms caused by Clostridium perfringens. The Clostridium perfringens protein Mbp provided by the application has the potential to be used as a Clostridium perfringens subunit vaccine.

The invention discloses a human-derived anti-respiratory syncytial virus neutralizing antibody RS414 and application of the human-derived anti-respiratory syncytial virus neutralizing antibody RS414. The antibody RS414 is obtained by screening by using a phage surface presentation technology. The antibody specifically recognizes the respiratory syncytial virus particle antigen, aims at the F protein of the respiratory syncytial virus, has obvious enzyme-linked immunosorbent assay reaction with the respiratory syncytial virus, and has a neutralizing activity function of resisting respiratory syncytial virus infection. The antibody provided by the invention can be prepared into a specific antibody drug for preventing and treating respiratory syncytial virus infection, and can be used for clinically preventing or treating lower respiratory tract infection, especially severe lower respiratory tract infection (pneumonia and capillary bronchitis) caused by the respiratory syncytial virus.

The invention relates to the technical field of tumor immunotherapy, in particular to tumor neoantigen polypeptide and a separation and screening method thereof. The amino acid sequence of the tumor neoantigen polypeptide provided by the invention is shown as SEQ ID NO.1, 2, 3 or 4. The tumor neoantigen polypeptide has high affinity with HLA molecules, can induce generation of tumor specific T cells, further generates immune response of targeting tumor cells, can be used as a target spot for clinical treatment or diagnosis of tumors, and has a good application prospect in tumor immunotherapy. The method for separating and screening the tumor neoantigen polypeptide provided by the invention solves the problem that the neoantigen of a non-surgical treatment patient cannot be obtained by the existing method, and provides an effective method for developing the tumor neoantigen polypeptide.

The invention belongs to the technical field of medicines, and discloses an active targeting nano preparation for enhancing tumor immunotherapy as well as a preparation method and application of the active targeting nano preparation. A metal organic framework nanoparticle siRNAPD-L1 (at) ZIF-8 entrapped with siRNAPD-L1 is prepared through electrostatic adsorption, then the surface of the metal organic framework nanoparticle siRNAPD-L1 (at) ZIF-8 is modified with HA to prepare siRNAPD-L1 (at) HA-ZIF-8, the nano-drug realizes specific accumulation of tumor tissues through active targeting and releases Zn < 2 + > ions and siRNAPD-L1 through acid-sensitive splitting decomposition, the Zn < 2 + > ions induce pyroptosis of cells and cause immunogenic death, and the siRNAPD-L1 and the siRNAPD-L1 can be used for preparing the nano-drug. The in-vivo immune response is activated; the siRNAPD-L1 can specifically silence the PD-L1 gene in tumor cells and reduce the expression of PD-L1 protein, and the siRNAPD-L1 and the PD-L1 can synergistically play an anti-tumor role. The method is simple in preparation process, low in cost, good in stability and high in repeatability. The active targeting nano preparation disclosed by the invention is beneficial to solving the problems that siRNAPD-L1 is unstable in systemic circulation, lacks targeting and the like, so that the delivery efficiency and the anti-tumor effect of siRNAPD-L1 are improved, and the active targeting nano preparation has a relatively good development prospect in the aspect of clinical application transformation.

The invention provides a chimeric polypeptide for enhancing immunogenicity of a tumor vaccine as well as a preparation method and application of the chimeric polypeptide. The chimeric polypeptide comprises at least two connected immunological enhancement molecular fragments, and the immunological enhancement molecular fragments comprise CD40L or a functional fragment thereof, and one or more selected from a group consisting of GM-CSF or a functional fragment thereof, HMGB1 or a functional fragment thereof, HSP70 or a functional fragment thereof, FLT3L or a functional fragment thereof, and OX40L or a functional fragment thereof. According to the chimeric polypeptide provided by the invention, the mRNA has a good immunological enhancement effect in cells, antigen-specific cellular immune response can be remarkably induced, and the chimeric polypeptide serving as an immunologic adjuvant can be used for constructing an anti-tumor drug (such as an mRNA vaccine) with a better tumor treatment effect.

The invention discloses a Pt (at) Ag (at) Te-anti-PD-L1 near-infrared two-region fluorescent probe as well as a preparation method and application thereof, and belongs to the technical field of biomedical materials, the Pt (at) Ag (at) Te-anti-PD-L1 near-infrared two-region fluorescent probe takes a Pt (at) Ag (at) Te nanostructure as a core, and the surface of the Pt (at) Ag (at) Te nanostructure is modified with an anti-PD-L1 antibody; the near-infrared two-region fluorescent probe combines the functions of targeted fluorescence imaging and mild photo-thermal immune regulation, can realize efficient tumor diagnosis and precise treatment, and has the core advantages of mild photo-thermal treatment guided by fluorescence visualization, induction of anti-tumor immune response, enhancement of the treatment effect and reduction of the recurrence risk. Besides, the near-infrared two-region fluorescent probe can generate a mild heat effect under the irradiation of near-infrared light, regulate and control immune response in a tumor microenvironment, and overcome the problems of drug resistance and low response rate of immunotherapy.

To provide acute myeloid leukemia antigen targets for chimeric receptors and methods of using same.SOLUTION: There is provided an isolated immunoresponsive cell comprising (a) a first chimeric receptor comprising an extracellular antigen-binding domain that binds to a first antigen, and (b) a second chimeric receptor comprising an extracellular antigen-binding domain that binds to a second antigen, wherein each antigen is selected from a group consisting of FLT3, CD33, CLEC12A, MS4A3, VSTM1, LAT2, MLC1, CD131, GAPT, PRAM1, SLC22A16, SLC17A9, SPNS3, ADGRE2, IL3RA, CD117, CD93, IL1RAP, CD244, CCR1, LILRB2, PIEZO1, CD38, EMB, MYADM, LILRA2, CD300LF, and CD70, and wherein the first antigen is different from the second antigen.SELECTED DRAWING: Figure 1

The present invention relates to monoclonal antibodies to the HCV core lipid binding domain. The present invention provides monoclonal antibodies for detecting Hepatitis C Virus (HCV) antigens. The antibodies specifically immunoreact with at least one epitope of the lipid binding domain of amino acid residues 134-171 of the HCV core antigen. Further provided are immunoassay methods for detecting HCV infection using the antibodies, kits comprising the antibodies, and compositions.